The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? Evidence from a Meta-Analysis: CURCUMINOIDS AND CRP
Abstract
BACKGROUND: Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease (CVD). In this context, C-reactive protein (CRP) has been identified as a strong predictor and independent risk factor of CVD. Curcuminoids are multifunctional natural product with promising cardioprotective and anti-inflammatory properties. Curcuminoids have been suggested to lower circulating levels of CRP, but clinical findings have not been consistent. OBJECTIVES: To pool the published results of clinical trials on the impact of supplementation with curcuminoids on circulating levels of CRP. METHODS: PubMed/MEDLINE and SCOPUS databases were searched for clinical trials reporting circulating CRP changes in individuals receiving curcuminoids. Effect sizes with 95% confidence intervals (CI) were calculated using a random-effects model. Inter-study heterogeneity was assessed using Cochran's Q and I(2) tests. Sensitivity analyses were conducted using leave-one-out method. RESULTS: Six trials comprising 172 subjects in the curcuminoids group and 170 subjects in the placebo group fulfilled the eligibility criteria and included in the meta-analysis. Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: -6.44 mg/L; 95% CI: -10.77 - -2.11; p = 0.004). This significant effect was maintained in subgroups of trials that used bioavailability-improved preparations of curcuminoids and had supplementation duration of ≥4 weeks, but not in the subgroups without these characteristics. CONCLUSIONS: Supplementation with curcuminoids may reduce circulating CRP levels. This effect appears to depend on the bioavailability of curcuminoids preparations and also duration of supplementation. Future well-designed and long-term trials are warranted to verify this effect of curcuminoids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 3×
“These include, but are not limited to, coadministration of curcuminoids with adjuvants, and using liposomes, micelles, phospholipid complexes, polymeric nanoparticles, and structural analogues of curcuminoids (Shehzad et al., 2010; Anand et al., 2007).”
BackgroundInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · cited 1×
“However, it has only recently been unveiled that circulating levels of this protein could serve as an independent predictor of CVD outcomes in both primary and secondary prevention (Liuzzo et al., 1994; Morrow et al., 1998; Lindahl et al., 2000; Ridker et al., 1997, 2005; Clearfield, 2005).”
BackgroundSimvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Sahebkar, A., Mohammadi, A., Atabati, A., Rahiman, S., Tavallaie, S., Iranshahi, M., Akhlaghi, S., Ferns, G. A., & Ghayour‐Mobarhan, M. (2013) · Phytotherapy Research · doi:10.1002/ptr.4952 · Cited by 183
Self-citation
Cited by
Curcumin: A Review of Its Effects on Human Health
Hewlings, S., & Kalman, D. (2017) · Foods · doi:10.3390/foods6100092 · Cited by 2,720
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double‐Blind Placebo‐Controlled Trial
Panahi, Y., Rahimnia, A., Sharafi, M., Alishiri, G., Saburi, A., & Sahebkar, A. (2014) · Phytotherapy Research · doi:10.1002/ptr.5174 · Cited by 310
Self-citationHaroyan, A., Mukuchyan, V., Mkrtchyan, N., Minasyan, N., Gasparyan, S., Sargsyan, A., Narimanyan, M., & Hovhannisyan, A. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2062-z · Cited by 232
Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study
Lopresti, A. L., Maes, M., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.001 · Cited by 216
Metadata
- Authors
- Sahebkar, A.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2013-08-07
- Volume
- 28
- Issue
- 5
- Pages
- 633-642
- ISSN
- 0951-418X (ISSN-L)
- OpenAlex
- W2164737140
- Cited by
- 303
- References
- 8
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
